Medicis Settlement - Additional Information (Detail) - USD ($) $ in Millions |
1 Months Ended | 6 Months Ended | 12 Months Ended | |
---|---|---|---|---|
Oct. 31, 2012 |
Jun. 30, 2017 |
Dec. 31, 2014 |
Dec. 31, 2013 |
|
Medicis Pharmaceutical Corporation | ||||
Settlement And Termination [Line Items] | ||||
Settlement consideration payable | $ 25.0 | |||
Upfront payment paid | 7.0 | |||
Medicis Pharmaceutical Corporation | Proceeds Sharing Arrangement | ||||
Settlement And Termination [Line Items] | ||||
Settlement agreement, payable | $ 14.0 | |||
Settlement payment | $ 7.1 | $ 6.9 | ||
Medicis Pharmaceutical Corporation | Product Approval Payment Derivative | ||||
Settlement And Termination [Line Items] | ||||
Derivative liability for the Product Approval Payment | $ 2.2 | |||
Remaining contractual term (in years) | 3 years | |||
Risk-free interest rate | 1.55% | |||
Fair value assumptions, credit risk adjustment (percent) | 7.00% | |||
Valeant Pharmaceuticals International, Inc. | Product Approval Payment Derivative | ||||
Settlement And Termination [Line Items] | ||||
Accrued milestone obligations | $ 4.0 |